{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:37:25Z","timestamp":1788824245918,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012435","name":"Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan","doi-asserted-by":"publisher","award":["ETK2025030"],"award-info":[{"award-number":["ETK2025030"]}],"id":[{"id":"10.13039\/501100012435","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012435","name":"Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan","doi-asserted-by":"publisher","award":["ETK2025029"],"award-info":[{"award-number":["ETK2025029"]}],"id":[{"id":"10.13039\/501100012435","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003351","name":"Foundation for Research and Training of Health Professionals of Extremadura","doi-asserted-by":"publisher","award":["2022ZQNZD012"],"award-info":[{"award-number":["2022ZQNZD012"]}],"id":[{"id":"10.13039\/501100003351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2023A04J1257"],"award-info":[{"award-number":["2023A04J1257"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinthera.2025.09.001","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T22:23:30Z","timestamp":1759789410000},"page":"1069-1075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world Hepatobiliary Toxicity After Bispecific T-Cell Engager Therapy: A 10-Year Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System and the World Health Organization's Global Individual Case Safety Report Database"],"prefix":"10.1016","volume":"47","author":[{"given":"Rong","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-2099","authenticated-orcid":false,"given":"Yingyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.09.001_bib0001","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.17622","article-title":"Taking a BiTE out of the CAR T space race","volume":"195","author":"Patel","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0002","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0003","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-024-00989-w","article-title":"Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives","volume":"14","author":"Abou Dalle","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0005","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40264-018-0760-1","article-title":"Benefit\u2013risk assessment of blinatumomab in the treatment of relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Stein","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0006","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125557s013lbl.pdf. Accessed April 6, 2025."},{"key":"10.1016\/j.clinthera.2025.09.001_bib0007","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761309s000lbl.pdf. Accessed April 6, 2025."},{"key":"10.1016\/j.clinthera.2025.09.001_bib0008","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761324s000lbl.pdf. Accessed April 6, 2025."},{"key":"10.1016\/j.clinthera.2025.09.001_bib0009","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761263s000lbl.pdf. Accessed April 6, 2025."},{"key":"10.1016\/j.clinthera.2025.09.001_bib0010","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf. Accessed April 6, 2025."},{"key":"10.1016\/j.clinthera.2025.09.001_bib0011","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761345Orig1s000lbl.pdf (last access on April 6, 2025)."},{"key":"10.1016\/j.clinthera.2025.09.001_bib0012","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf. Accessed April 6, 2025."},{"key":"10.1016\/j.clinthera.2025.09.001_bib0013","doi-asserted-by":"crossref","first-page":"S1237","DOI":"10.14309\/01.ajg.0000598360.95136.ce","article-title":"2207 Blinatumomab-induced hepatic sinusoidal obstruction syndrome","volume":"114","author":"Tabbalat","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0014","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ccr3.604","article-title":"Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant","volume":"4","author":"Khan","year":"2016","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0015","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102684","article-title":"Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0018","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ijc.34332","article-title":"Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis","volume":"152","author":"Gu","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0019","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0020","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2022"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0021","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0022","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11912-019-0753-y","article-title":"Cytokine release syndrome with the novel treatments of acute lymphoblastic leukemia: pathophysiology, prevention, and treatment","volume":"21","author":"Aldoss","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clinthera.2025.09.001_bib0023","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.22895","article-title":"Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex","volume":"49","author":"Lucena","year":"2009","journal-title":"Hepatology"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:55:55Z","timestamp":1774947355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825003078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0149291825003078"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Hepatobiliary Toxicity After Bispecific T-Cell Engager Therapy: A 10-Year Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System and the World Health Organization's Global Individual Case Safety Report Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}